Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
ApexOnco Front Page
Recent articles
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.